Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 3/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | AKT1S1 | Q96B36 | 1/20 | 0.48 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18824466 | 1.00 | DPP4 (0.60) | DPP4ALDH1A1THRBP2RX7TP53 | |
| SCHEMBL16461842 | 0.94 | DPP4 (0.55) | DPP4ALDH1A1THRBP2RX7TP53 | |
| SCHEMBL16461973 | 0.84 | RPS6KB1 (0.50) | THRBP2RX7TP53LMNAAKT1S1 | |
| SCHEMBL16461381 | 0.84 | RPS6KB1 (0.50) | DPP4ALDH1A1THRBP2RX7TP53 | |
| SCHEMBL3470901 | 0.83 | ACHE (0.53) | DPP4ALDH1A1P2RX7MAPTAKT1S1 | |
| SCHEMBL15797503 | 0.83 | DPP4 (0.53) | DPP4ALDH1A1THRBP2RX7TP53 | |
| SCHEMBL20746267 | 0.83 | DPP4 (0.64) | DPP4ALDH1A1THRBRPS6KB1 | |
| SCHEMBL856294 | 0.83 | DPP4 (0.64) | DPP4ALDH1A1THRBRPS6KB1 | |
| SCHEMBL3669763 | 0.83 | RPS6KB1 (0.49) | ALDH1A1THRBP2RX7TP53LMNA | |
| SCHEMBL8276866 | 0.81 | DPP4 (0.58) | DPP4ALDH1A1THRBP2RX7TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180319786-A1 | INHIBITOR OF THE P2X7 RECEPTOR | MINDIMMUNE THERAPEUTICS, INC. | 2018-11-08 | — | — | US | claimed |
| EP-3371180-A1 | INHIBITOR OF THE P2X7 RECEPTOR | H. Lundbeck A/S (DK) | 2018-09-12 | — | — | EP | claimed |
| US-9718774-B2 | Indole carboxamide derivatives as P2X7 receptor antagonist | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-08-01 | — | — | US | claimed |
| WO-2017076825-A1 | INHIBITOR OF THE P2X7 RECEPTOR | H. LUNDBECK A/S (DK) | 2017-05-11 | — | — | WO | claimed |
| EP-2931717-B1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-12-07 | — | — | EP | claimed |
| US-20150322008-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONIST | ACTELION PHARMACEUTICALS LTD (CH) | 2015-11-12 | — | — | US | claimed |
| EP-2931717-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2015-10-21 | — | — | EP | claimed |
| WO-2014091415-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-06-19 | — | — | WO | claimed |
| US-20190307766-A1 | CYCLIC AMINES | MINDIMMUNE THERAPEUTICS, INC. | 2019-10-10 | — | — | US | disclosed |
| EP-3536689-A1 | 2-(CYCLIC AMINEETHYL)BENZAMIDE DERIVATIVES AS P2X7 INHIBITORS | MindImmune Therapeutics, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-2906549-B1 | N-(2-(CYCLIC AMINE)ETHYL)BENZAMIDE DERIVATIVES AS P2X7 INHIBITORS | MINDIMMUNE THERAPEUTICS INC (US) | 2019-04-17 | — | — | EP | disclosed |
| US-10124010-B2 | Cyclic amines | MINDIMMUNE THERAPEUTICS, INC. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180319786-A1 | INHIBITOR OF THE P2X7 RECEPTOR | MINDIMMUNE THERAPEUTICS, INC. | 2018-11-08 | — | — | US | disclosed |
| EP-3371180-A1 | INHIBITOR OF THE P2X7 RECEPTOR | H. Lundbeck A/S (DK) | 2018-09-12 | — | — | EP | disclosed |
| WO-2014091415-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-06-19 | — | — | WO | disclosed |
| US-20140107335-A1 | Cyclic Amines | H. LUNDBECK A/S (DK) | 2014-04-17 | — | — | US | disclosed |
| WO-2014057080-A2 | CYCLIC AMINES | H. LUNDBECK A/S (DK) | 2014-04-17 | — | — | WO | disclosed |
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2005095343-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319786-A1 | INHIBITOR OF THE P2X7 RECEPTOR | P2RX7, P2RX2, P2RX1 | DPP4 662/4885ALDH1A1 2655/4885THRB 774/4885 |
| US-20070197522-A1 | Dpp-iv inhibitors | DPP7, DPP4, DPP3 | DPP4 2/4885ALDH1A1 2070/4885THRB 1476/4885 |
| US-20150322008-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONIST | P2RX3, P2RX7, P2RX1 | DPP4 1374/4885ALDH1A1 1594/4885THRB 568/4885 |
| US-20190307766-A1 | CYCLIC AMINES | P2RX7, ADORA2A, P2RX2 | DPP4 3144/4885ALDH1A1 1554/4885THRB 742/4885 |
| US-20140107335-A1 | Cyclic Amines | P2RX7, ADORA2A, P2RX2 | DPP4 3144/4885ALDH1A1 1554/4885THRB 742/4885 |
| US-10124010-B2 | Cyclic amines | P2RX7, ADORA2A, P2RX2 | DPP4 3144/4885ALDH1A1 1554/4885THRB 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.